Immunic to participate in scientific and investor conferences in march

New york , march 3, 2025 /prnewswire/ --  immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in march: march 4-7: 34th annual meeting of the society for virology. two abstracts have been accepted for abstract talk presentations at this conference in hamburg, germany.
IMUX Ratings Summary
IMUX Quant Ranking